Government-Owned Inventions; Availability for Licensing, 50864-50865 [2022-17730]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES 50864 Federal Register / Vol. 87, No. 159 / Thursday, August 18, 2022 / Notices advisory committee information line to learn about possible modifications before coming to the meeting. SUPPLEMENTARY INFORMATION: Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On October 6, 2022, the committee will meet in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2023 Southern Hemisphere Influenza Season. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the time of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting. Procedure: On October 6, 2022, from 8:30 a.m. to 12:40 p.m. EasternTime, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. All electronic and written submissions submitted to the Docket (see ADDRESSES) on or before September 28, 2022, will be provided to the committee. Comments received after September 28, 2022, and by October 5, 2022, will be taken into consideration by FDA. Oral presentations from the public will be scheduled between approximately 10:40 a.m. and 11:40 a.m. EasternTime. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, along with their names, email addresses, and direct contact phone numbers of proposed participants, on or before 12 p.m. Eastern Time on September 21, 2022. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their VerDate Sep<11>2014 17:42 Aug 17, 2022 Jkt 256001 request to speak by 6 p.m. September 22, 2022. For press inquiries, please contact the Office of Media Affairs at fdaoma@ fda.hhs.gov or 301–796–4540. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Sussan Paydar or Prabhakara Atreya (see FOR FURTHER INFORMATION CONTACT) at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at https://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: August 15, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022–17784 Filed 8–17–22; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Council of Councils, September 8, 2022, 10:30 a.m. to September 9, 2022, 03:00 p.m., virtual meeting which was published in the Federal Register on, August 8, 2022, FR Doc 2022–16892, 87 FR 48189. The notice is being amended to change the start and end times of the open portion of the meeting on September 8, 2022 from 10:30 a.m. to 10:15 a.m. and end time 3:00 p.m. to 3:30 p.m. and change the end time of the open portion of the meeting on September 9, 2022 from 3:10 p.m. to 3:15 p.m. Dated: August 12, 2022. David W Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17726 Filed 8–17–22; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301–767–5189, or dawn.taylor-mulneix@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: SUMMARY: SARS–CoV–2 Infection of Human Lung Epithelial Cells Triggers a CellMediated Acute Fibrin Fibrosis Description of Technology Scientists at National Institute of Allergy and Infectious Diseases (NIAID) have developed a method of treatment for virus-induced lung fibrosis using nebulized thrombin inhibitors. Since March 2020, the World Health Organization (WHO) estimates that 564 million people have been infected with SARS–CoV–2 world-wide. Lung fibrosis is a major factor associated with SARS– CoV–2 infections and can contribute to mortality. Additionally, severe SARS– CoV–2 cases can result in long-term pulmonary disease due to lung fibrosis. At present, attempts to treat lung fibrosis developed during a SARS–CoV– 2 infection using intravenous heparin have been unsuccessful. NIAID scientists have discovered a previously unknown acute fibrosis mechanism mediated by SARS–CoV–2 infected primary lung epithelium, and have developed an innovative method of treating lung fibrosis using nebulized thrombin inhibitors. This technology is available for licensing for commercial development E:\FR\FM\18AUN1.SGM 18AUN1 Federal Register / Vol. 87, No. 159 / Thursday, August 18, 2022 / Notices in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • Innovative method of treatment for virus-induced lung fibrosis • A multi-targeted approach could decrease lung-term symptoms associated with SARS–CoV–2 Competitive Advantages • Addresses the pathology at the proper location instead of indiscriminately Development Stage • Pre-Clinical Inventors: Peter Sun and Rachel Erickson, all of NIAID. Intellectual Property: US Provisional Application 63/388,498 (HHS Reference No. E–157–2022–0–US–01) filed on 12 July 2022. Licensing Contact: To license this technology, please contact Dawn TaylorMulneix at 301–767–5189, or dawn.taylor-mulneix@nih.gov, and reference E–157–2022. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301– 767–5189, or dawn.taylor-mulneix@ nih.gov. Dated: August 12, 2022. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2022–17730 Filed 8–17–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the National Advisory Allergy and Infectious Diseases Council. The meeting will be open to the public. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov). Individuals who need special VerDate Sep<11>2014 17:42 Aug 17, 2022 Jkt 256001 assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Allergy and Infectious Diseases Council. Date: September 12, 2022. Open: 10:30 a.m. to 11:30 a.m. Agenda: Report of Institute Director. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Closed: 11:45 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Contact Person: Matthew J. Fenton, Ph.D., Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892, 301–496–7291, fentonm@ niaid.nih.gov. Name of Committee: National Advisory Allergy and Infectious Diseases Council, Acquired Immunodeficiency Syndrome Subcommittee. Date: September 12, 2022. Closed: 8:30 a.m. to 10:15 a.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Open: 1:00 p.m. to 4:00 p.m. Agenda: Report of Division Director and Division Staff. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Contact Person: Matthew J. Fenton, Ph.D., Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892, 301–496–7291, fentonm@ niaid.nih.gov. Name of Committee: National Advisory Allergy and Infectious Diseases Council; Microbiology and Infectious Diseases Subcommittee. Date: September 12, 2022. Closed: 8:30 a.m. to 10:15 a.m. PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 50865 Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Open: 1:00 p.m. to 4:00 p.m. Agenda: Report of Division Director and Division staff. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Contact Person: Matthew J. Fenton, Ph.D., Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892, 301–496–7291, fentonm@ niaid.nih.gov. Name of Committee: National Advisory Allergy and Infectious Diseases Council; Acquired Immune Deficiency Syndrome Subcommittee. Date: September 12, 2022. Closed: 8:30 a.m. to 10:15 a.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Open: 1:00 p.m. to 4:00 p.m. Agenda: Report of Division Director and Division Staff. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F30, Rockville, MD 20892 (Virtual Meeting). Contact Person: Matthew J. Fenton, Ph.D., Director, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 4F50, Bethesda, MD 20892, 301–496–7291, fentonm@ niaid.nih.gov. Any interested person may file written comments within 15 days of the meeting with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// www.niaid.nih.gov/about/advisory-council, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 12, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17728 Filed 8–17–22; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 87, Number 159 (Thursday, August 18, 2022)]
[Notices]
[Pages 50864-50865]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17730]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189, 
or [email protected]. Licensing information may be obtained 
by communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:

SARS-CoV-2 Infection of Human Lung Epithelial Cells Triggers a Cell-
Mediated Acute Fibrin Fibrosis

Description of Technology

    Scientists at National Institute of Allergy and Infectious Diseases 
(NIAID) have developed a method of treatment for virus-induced lung 
fibrosis using nebulized thrombin inhibitors. Since March 2020, the 
World Health Organization (WHO) estimates that 564 million people have 
been infected with SARS-CoV-2 world-wide. Lung fibrosis is a major 
factor associated with SARS-CoV-2 infections and can contribute to 
mortality. Additionally, severe SARS-CoV-2 cases can result in long-
term pulmonary disease due to lung fibrosis. At present, attempts to 
treat lung fibrosis developed during a SARS-CoV-2 infection using 
intravenous heparin have been unsuccessful.
    NIAID scientists have discovered a previously unknown acute 
fibrosis mechanism mediated by SARS-CoV-2 infected primary lung 
epithelium, and have developed an innovative method of treating lung 
fibrosis using nebulized thrombin inhibitors.
    This technology is available for licensing for commercial 
development

[[Page 50865]]

in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for 
further development and evaluation under a research collaboration.

Potential Commercial Applications

 Innovative method of treatment for virus-induced lung fibrosis
 A multi-targeted approach could decrease lung-term symptoms 
associated with SARS-CoV-2

Competitive Advantages

 Addresses the pathology at the proper location instead of 
indiscriminately

Development Stage

 Pre-Clinical
    Inventors: Peter Sun and Rachel Erickson, all of NIAID.
    Intellectual Property: US Provisional Application 63/388,498 (HHS 
Reference No. E-157-2022-0-US-01) filed on 12 July 2022.
    Licensing Contact: To license this technology, please contact Dawn 
Taylor-Mulneix at 301-767-5189, or [email protected], and 
reference E-157-2022.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or 
[email protected].

    Dated: August 12, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-17730 Filed 8-17-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.